ASIAMEDIC LIMITED — Share Issue/Capital Change 2025

Jun 9, 2025

ASIAMEDIC LIMITED

(Incorporated in the Republic of Singapore)

(Company Registration No. 197401556E)

COMPLETION OF PROPOSED SELECTIVE CAPITAL REDUCTION OF THE COMPANY

1. INTRODUCTION

• 1.1 The board of directors (the “ Board ”) of AsiaMedic Limited (the “ Company ”, and together with its subsidiaries, the “ Group ”) refers to the announcement of the Company dated 24 April 2025 (the “ Previous Announcement ”) and the circular to Shareholders dated 2 April 2025 (“ Circular ”) in relation to the Proposed Selective Capital Reduction. Unless otherwise defined, capitalised terms herein shall have the same meaning as ascribed to them in the Previous Announcement and the Circular.

• 1.2 As announced in the Previous Announcement, the resolution in relation to the Proposed Selective Capital Reduction (the “ Selective Capital Reduction Resolution ”) was duly passed by the Shareholders in the annual general meeting of the Company held on 24 April 2025.

2. COMPLETION OF THE PROPOSED SELECTIVE CAPITAL REDUCTION

• 2.1 Further to the Previous Announcement and the Circular, the Board is pleased to announce that the Company has complied with the requirements under Section 78C(1)(c) of the Companies Act 1967 (the “ Act ”), and that no application for the cancellation of the Selective Capital Reduction Resolution has been made by any creditor within the prescribed time-frame pursuant to the Act.

• 2.2 The Company has accordingly lodged the relevant documents required under Sections 78E(2)(c) and (d) of the Act with the Accounting and Corporate Regulatory Authority of Singapore on 9 June 2025.

• 2.3 The Proposed Selective Capital Reduction is therefore effective as at 9 June 2025. Accordingly, the issued and fully paid-up share capital of the Company with effect therefrom is S$33,394,437 comprising 1,129,522,270 ordinary shares (excluding 100,000 treasury shares).

By Order of the Board

Foo Soon Soo (Ms) Company Secretary

9 June 2025

This announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954.

1